Prelude Therapeutics Incorporated reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 27.72 million compared to USD 29.47 million a year ago. Basic loss per share from continuing operations was USD 0.58 compared to USD 0.63 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.891 USD | +1.07% | +4.88% | -8.87% |
31/05 | Prelude Therapeutics Files for $400 Million Mixed Shelf | MT |
07/05 | Prelude Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.87% | 211M | |
+48.93% | 54.63B | |
-6.53% | 39.92B | |
+37.07% | 38.82B | |
+14.41% | 26.86B | |
-11.17% | 26.22B | |
-21.84% | 18.78B | |
+26.82% | 12.21B | |
+0.97% | 12.16B | |
+28.19% | 11.94B |
- Stock Market
- Equities
- PRLD Stock
- News Prelude Therapeutics Incorporated
- Prelude Therapeutics Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2023